Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer

demystifying the connections

Clara Inkyung Lee, Howard Gurney

Research output: Contribution to journalArticle

2 Citations (Scopus)


The role of the selective oestrogen receptor modulator, tamoxifen, is well established in the treatment of hormone sensitive breast cancer. The metabolism of tamoxifen to its active metabolites is however complex. Despite much research, a conclusive stance on the clinical implications of CYP2D6, active metabolites including endoxifen in efficacy and toxicity, is yet to be reached. Herein we examine the literature to clarify the connections between tamoxifen, CYP2D6 and endoxifen with resultant clinical recommendations.

Original languageEnglish
Pages (from-to)4-10
Number of pages7
JournalCancer Forum
Issue number3
Publication statusPublished - 1 Nov 2016


Cite this